Lonza cuts 2009 guidance 14% and plans workforce cuts

By Gareth Macdonald

- Last updated on GMT

Related tags Economics

Lonza cuts 2009 earning guidance and may reduce its workforce under “Project Bond” cost cutting plan after a Q3 characterized by an “accumulation of unexpected events”

Late last week, the Swiss drug ingredients maker lowered its full year guidance to CHF380m (€252m), down 13.8 per cent on it previous target, citing order cancellations and postponements as the basis for the move.

And, while Lonza did not respond to in-PharmaTechnologist’s request for more information, it is understood that a key factor in the firm’s move was the 18-month delay to a cell therapy drug project in which it is involved.

Other factors affecting the Basel-headquartered firm since the end of September include lower-than-expected demand for its exclusive synthesis business and nutrition ingredients range, as well as ongoing “margin pressure on microbial control and performance intermediates​.”

CEO Stefan Borgas was quick to respond to Lonza’s unexpected Q3 problems, setting out a programme of cost cutting measures designed to save between CHF60m and CHF80m over the next two years.

Borgas told analysts that: “By no means are we in a recovery mode in any of our markets around the world,"​ adding that the firm will reduce its 8,500 strong workforce by 5 per cent and may close some of its manufacturing facilities.

He also said that Lonza will adapt some of its biomanufacturing plants so they can cater for smaller-scale clinical Phase II and III projects in order to boost capacity utilisation.

Despite this, Borgas said that: “Lonza isn't in a crisis. We will continue to expand our project pipeline in biologicals and chemicals and will sign additional pipeline deals to add to the long-term health of our business​.”

However, Lonza’s announcement was accompanied by a 25 per cent fall, to CHF80, in its share price on the Zurich stock exchange.

Expansion through acquisitions

Despite the planned cutbacks and capacity reductions, Lonza still plans to expand its custom manufacturing project pipeline and increase longer-term customer collaborations.

The firm said it is still seeking to build its contract research and manufacturing offering through acquisitions, reiterating comments it made after withdrawing its bid for Canadian contractor Patheon last month.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more